Dr. Reddy’s subsidiary announces Zembrace SymTouch U.S. availability

HYDERABAD, India. — Dr. Reddy’s Laboratories subsidiary Promius Pharma announced Tuesday that its Zembrace SymTouch (sumatriptan injection) is now commercially available in the United Stated. 

 

The pre-filled, low-dose autoinjector contains 3 mg of sumatriptan, which can lead to rapid migraine relief. 

 

 “Zembrace SymTouch is a welcome addition to the toolkit for acute treatment of migraine,” said Dr. Roger Cady, associate executive chairman of the National Headache Foundation. “This 3-mg, easy-to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of Zembrace SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.” Zembrace SymTouch is available as a box of 4 autoinjectors.”